IN2015DN03203A - - Google Patents
Info
- Publication number
- IN2015DN03203A IN2015DN03203A IN3203DEN2015A IN2015DN03203A IN 2015DN03203 A IN2015DN03203 A IN 2015DN03203A IN 3203DEN2015 A IN3203DEN2015 A IN 3203DEN2015A IN 2015DN03203 A IN2015DN03203 A IN 2015DN03203A
- Authority
- IN
- India
- Prior art keywords
- binding agent
- impurities
- mixture
- cytotoxic agent
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261709871P | 2012-10-04 | 2012-10-04 | |
| PCT/US2013/063503 WO2014055893A1 (en) | 2012-10-04 | 2013-10-04 | Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03203A true IN2015DN03203A (ko) | 2015-10-02 |
Family
ID=50435480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3203DEN2015 IN2015DN03203A (ko) | 2012-10-04 | 2013-10-04 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150307596A1 (ko) |
| EP (1) | EP2903450A4 (ko) |
| JP (1) | JP2015535215A (ko) |
| CN (1) | CN105208876A (ko) |
| AU (1) | AU2013326897A1 (ko) |
| CA (1) | CA2886996A1 (ko) |
| HK (1) | HK1213148A1 (ko) |
| IL (1) | IL238111A0 (ko) |
| IN (1) | IN2015DN03203A (ko) |
| MX (1) | MX2015004258A (ko) |
| RU (1) | RU2015116883A (ko) |
| SG (1) | SG11201502430QA (ko) |
| WO (1) | WO2014055893A1 (ko) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1928503B1 (en) | 2005-08-24 | 2012-10-03 | ImmunoGen, Inc. | Process for preparing maytansinoid antibody conjugates |
| PL2437790T3 (pl) | 2009-06-03 | 2019-09-30 | Immunogen, Inc. | Sposoby sprzęgania |
| KR20220123130A (ko) | 2011-03-29 | 2022-09-05 | 이뮤노젠 아이엔씨 | 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조 |
| SG11201502429YA (en) | 2012-10-04 | 2015-04-29 | Immunogen Inc | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
| GB201616758D0 (en) * | 2016-10-03 | 2016-11-16 | Ge Healthcare Bio Sciences Ab | Novel chromatography media |
| CN108549763B (zh) * | 2018-04-09 | 2021-06-01 | 电子科技大学 | 一种用于离子推进器数值模拟的电荷交换碰撞mcc方法 |
| CN118290513A (zh) * | 2024-06-05 | 2024-07-05 | 东曜药业有限公司 | 一种去除抗体偶联药物中游离小分子的阴离子柱层析方法及抗体偶联药物 |
| CN118290514A (zh) * | 2024-06-05 | 2024-07-05 | 东曜药业有限公司 | 基于阴离子膜的抗体偶联药物的纯化方法及抗体偶联药物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003057163A2 (en) * | 2002-01-03 | 2003-07-17 | Smithkline Beecham Corporation | Methods for preparing immunoconjugates |
| US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| US20060182750A1 (en) * | 2005-02-11 | 2006-08-17 | Immunogen, Inc. | Process for preparing stable drug conjugates |
| US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
| EP1928503B1 (en) * | 2005-08-24 | 2012-10-03 | ImmunoGen, Inc. | Process for preparing maytansinoid antibody conjugates |
| PL2437790T3 (pl) * | 2009-06-03 | 2019-09-30 | Immunogen, Inc. | Sposoby sprzęgania |
| KR20220123130A (ko) * | 2011-03-29 | 2022-09-05 | 이뮤노젠 아이엔씨 | 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조 |
-
2013
- 2013-10-04 IN IN3203DEN2015 patent/IN2015DN03203A/en unknown
- 2013-10-04 JP JP2015535827A patent/JP2015535215A/ja active Pending
- 2013-10-04 AU AU2013326897A patent/AU2013326897A1/en not_active Abandoned
- 2013-10-04 MX MX2015004258A patent/MX2015004258A/es unknown
- 2013-10-04 US US14/430,744 patent/US20150307596A1/en not_active Abandoned
- 2013-10-04 CN CN201380061514.1A patent/CN105208876A/zh active Pending
- 2013-10-04 EP EP13843881.7A patent/EP2903450A4/en not_active Withdrawn
- 2013-10-04 WO PCT/US2013/063503 patent/WO2014055893A1/en active Application Filing
- 2013-10-04 CA CA 2886996 patent/CA2886996A1/en not_active Abandoned
- 2013-10-04 RU RU2015116883A patent/RU2015116883A/ru not_active Application Discontinuation
- 2013-10-04 SG SG11201502430QA patent/SG11201502430QA/en unknown
-
2015
- 2015-04-02 IL IL238111A patent/IL238111A0/en unknown
-
2016
- 2016-02-04 HK HK16101358.6A patent/HK1213148A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2903450A1 (en) | 2015-08-12 |
| EP2903450A4 (en) | 2016-05-11 |
| US20150307596A1 (en) | 2015-10-29 |
| SG11201502430QA (en) | 2015-04-29 |
| MX2015004258A (es) | 2015-09-25 |
| CA2886996A1 (en) | 2014-04-10 |
| CN105208876A (zh) | 2015-12-30 |
| WO2014055893A1 (en) | 2014-04-10 |
| IL238111A0 (en) | 2015-05-31 |
| HK1213148A1 (zh) | 2016-06-30 |
| AU2013326897A1 (en) | 2015-05-07 |
| RU2015116883A (ru) | 2016-11-27 |
| JP2015535215A (ja) | 2015-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN03203A (ko) | ||
| IN2015DN03202A (ko) | ||
| EP4253395A3 (en) | Processes for the preparation of carbohydrate conjugated rna agents | |
| MX2021005426A (es) | Ciclodextrina y formulaciones de conjugados anticuerpo-farmaco. | |
| PH12015500243A1 (en) | Glycoconjugation processes and compositions | |
| MX2016017355A (es) | Lipido que comprende acido docosapentaenoico. | |
| NZ708727A (en) | Conjugate compounds | |
| MX2015005792A (es) | Compuestos de conjugado antisentido anti apob. | |
| MD20150091A2 (ro) | Compuşi antivirali | |
| CA2830549C (en) | Methods and compositions for preparing noribogaine from voacangine | |
| IN2015DN03327A (ko) | ||
| PH12014502032A1 (en) | Treatment of brain cancer | |
| MX2013000958A (es) | Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma. | |
| MX347882B (es) | Procedimiento mejorado para preparar (3e, 7e)-homofarnesol. | |
| MX2013013649A (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
| MX2018005785A (es) | Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos. | |
| EP2576575A4 (en) | PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF | |
| PH12014501367A1 (en) | Processes for making magnolol and derivatives thereof | |
| PH12014501327A1 (en) | Processes for making magnolol analogs | |
| GEP201706708B (en) | Isoxazolidine derivatives | |
| WO2014159501A3 (en) | Processes for preparing tetrahydroisoquinolines | |
| IN2012DE00826A (ko) | ||
| WO2014030173A3 (en) | Improved process for preparation of atazanavir bisulfate | |
| IN2014KN02683A (ko) | ||
| IN2013CH04314A (ko) |